| Literature DB >> 25039776 |
Abstract
The current rapid development of nanotechnologies and engineered nanomaterials (ENM) will impact the society in a major fashion during the coming decades. This development also causes substantial safety concerns. Among the many promising applications of ENM, products that can be used for diagnosis and treatment of diseases, including conditions that affect the nervous system, are under development. ENM can pass the blood brain barrier (BBB) and accumulate within the brain. It seems that the nano-form rather than the bulk form of the chemicals pass the BBB, and that there is an inverse relationship between particle size and the ability to penetrate the BBB. Although translocation of ENM to the brain is possible during experimental conditions, the health relevance for real-life situations is far from clear. One major reason for this is that studies have been using nanoparticle concentrations that are far higher than the ones that can be expected during realistic exposures. However, very high exposure to the CNS can cause effects on neurotransmission, redox homeostasis and behavior. Available studies have been focusing on possible effects of the first generation of ENM. It will be necessary to study possible health effects also of expected novel sophisticated materials, independent of the outcome of present studies. The prospects for intended or targeted medical applications are promising since it has been shown that ENM can be made to pass the BBB and reach specific regions or cells within the brain.Entities:
Mesh:
Year: 2014 PMID: 25039776 PMCID: PMC4435026 DOI: 10.2174/0929867321666140716100449
Source DB: PubMed Journal: Curr Med Chem ISSN: 0929-8673 Impact factor: 4.530
Neurologically Related Nano-medicine Products on the Market.
| Indication | Composition | Product |
|---|---|---|
| Antiemetic | Nanocrystalline aprepitant, part of the group of neurokinin-1-receptor- antagonists | Emend |
| Atypical antipsychotic agent | Nanosized 9-hydroxyrisperidone, a dopamine antagonist | InvegaSustenna |
| Eating disorders | Nanocrystallinemegesterol acetate, synthetic derivative of progesterone | MegaceES |
| Multiple sclerosis | Copolymer of alanine, lysine, glutamic acid, tyrosine | Copaxone |
| Schizophrenia | Nanocrystalline paliperidone, 9-hydroxyrisperidone is a dopamine antagonist | InvegaSustenna |
Investigations on the Nervous System After ENM Exposure In Vivo
| ENM | Animal | Administration | Parameters / Dose | Effect | Refs. |
|---|---|---|---|---|---|
| TiO2 | CD-1 (ICR) mice | intranasal instillation | hydrophobic 1 µm or 10x40 nm; hydrophilic 50 or 10x50 nm with silica surface coating, 500 μg /per instillation, every second day for 30 days | accumulation in cerebral cortex and striatum of hydrophilic TiO₂, morphological changes of neurons in cerebral cortex, significant disturbance of the monoamine neurotransmitter levels in the sub-brain regions | [ |
| 80 CD (ICR) mice | intranasal administration | 5-6 nm, 2.5, 5 and 10 mg/kg for 90 days | oxidative damage in the brain via p38-Nrf-2 signaling pathway | [ | |
| Rats | inhalation | 21 nm, 12 mg/m3, 5.6 h/d for 3 d | age-dependent up-regulation of neurotrophin expression | [ | |
| Sprague-Dawley rats | subcutaneous injection of pregnant rats | 25-70 nm; surface area 20-25 m2/g; anatase | oxidative damage in the offspring hippocampus , | [ | |
| ICR mice | subcutaneous injection of pregnant mice | 25-70 nm, total 0.4 mg | changes in gene expression of offspring's brain | [ | |
| CD-1 (ICR) mice | injection into abdominal cavity | 5 nm, various doses from 5 to 150 mg/kg, daily for 14 days, anatase | at high doses some neurons changed morphology, increased oxidative stress | [ | |
| ICR mice | intravenous injection | 42 nm, 0, 140, 300, 645, or 1387 mg/kg, anatase | high dose caused acute toxicity effects in the brain, lung, spleen, liver, and kidney | [ | |
| Ag | Wistar rats | oral administration | 14 nm, 4.5 and 9 mg Ag-NP/kg/day, 9 mg kg/day Ag-ions | AgNP affected 5-HT, Ag-ions noradrenaline, both affected dopamine | [ |
| Sprague-Dawley rats | oral administration | 10 or 25 nm, 100, 500 mg/kg/day for 28 days | silver accumulation in the brain did not clear after 4 months | [ | |
| Sprague-Dawley rats | oral exposure | <20 nm noncoated, or <15 nm PVP-coated, 90 mg/kg , or AgNO3 9 mg/kg, for 28 days | AgNP and Ag ions showed similar effects, long retention of silver in brain and testis | [ | |
| ICR mice | intraperitoneal injection | 25 nm, 10, 25, and 50 mg/kg for 7 days | no effects on memory or on hippocampal neurogenesis | [ | |
| Wistar rats | intravenous administration | 20, 80 and 110 nm, 23-28 mg/ml, once daily for 5 consecutive days | small part of total silver accumulated in the brain | [ | |
| CuO | CD-1 (ICR) mice | intranasal instillation | 23.5 nm, 1, 10 and 40 mg/kg, every second day for 15 or 21 days | high level induced changes in neurotransmitter secretion | [ |
| Wistar rats | intraperitoneal injection | 60.6 nm, 0.5 mg/kg/day for 2 weeks | increased Cu accumulation in hippocampus, cognition deficits | [ | |
| CdSe/ZnS quantum dots | C57BL/6 mice | intranasal instillation | PEG2-PE-encapsulated | 3 h post exposure within the olfactory tract and olfactory bulb via axonal transport, activation of microglial cells | [ |
| Wistar rats | intrahippocampal infusion | 20 nm, (5 μl) for 2 h | induced autophagy | [ | |
| Animal | Administration | Parameters / Dose | Effect | Refs. | |
| Fe3O4 | SD rats | intranasal instillation | 30 nm, 20 µg total for 7 days | deposited from highest to lowest concentration in olfactory bulb, striatum, hippocampus, brain stem, cerebellum, and frontal cortex, and no other significant changes, 50% of Fe3O4-NPs remained in striatum and hippocampus 14 days post-instillation | [ |
| Albino Wistar rats | oral application | 30 nm or bulk, single dose of 500, 1000, 2000 mg/kg | small part of the total applied nano-Fe accumulated in the brain | [ | |
| depleted UO2 | Wistar rats | nose-only inhalation | 38 nm, 107 particles per cm3, 1 h | no incorporation in brain or olfactory portion of the brain | [ |
Investigations on the Nervous System After ENM Exposure In Vivo
| ENM | Cell Type | Parameters / Dose | Main Findings | Refs. |
|---|---|---|---|---|
| PC12 cells | 20 nm anatase, rutile; 24 h; 25-200 µg/ml | Anatase more toxic, concentration dependent; increased oxidative stress, apoptosis induction, G2/M arrest | [ | |
| Retinal ganglion cells | 60 nm; 24, 48, 72 h; 0.63-10.0 µg/ml | Increased ROS; apoptosis induction | [ | |
| SHSY5Y neuroblastoma cells | 60 nm; 3, 6, 24, 48 h; 0-80 µg/ml | Viability decrease; S-phase accumulation; apoptosis induction, genotoxicity | [ | |
| Primary rat cortex cells; mixed, neuron-enriched, astrocytes | 20 and 40 nm; Au as control; 7, 14, 21 days; 5-100 µg/ml | Uptake in astrocytes; increased cell death, Ca2+ influx, oxidative stress; stronger effects from 20 nm NP | [ | |
| Primary rat cortex cells | 20 nm; 3 days; 1, 5, 10, 50 µg/ml | Decreased cell viability; neurite and synapse degeneration | [ | |
| astrocytes | review | Up to 7 days treatment, no acute effects; instracellular accumulation of NP; increased HO-1 and MT levels | [ | |
| PC12 cells | 14 nm PVP-coated; 0.5, 5, 10 µg/ml; sub-nano fraction and AgAc in corresponding Ag-concentrations; 4-48 h | No uptake of Ag NP but Ag-presence detected intracellularly; apoptosis induction in all conditions on a comparable level | [64] | |
| astrocytes | review | Endocytotic uptake of NP; ferritin-binding of NP | [ | |
| Primary cultures from rat cerebellum and spinal cord; PC12 cells | 24 h; 100 µg/ml | Uptake in microglia more pronounced than in other primary cells; PC12 uptake even stronger; microglia proliferation | [ | |
| PC12 cells | 11 nm Fe3O4 PEG-shell; 24 h; 5-40 µg/ml | Lysosomal uptake; NGF-potentiation | [ | |
| PC12 cells | 20 and 50 nm; 12-48 h; 25 and 30 µg/ml | Decrease in survival; increased oxidative stress; inhibited NGF-induced differentiation | [ | |
| U87 astrocytoma cells | 12 nm; 48 h; 0.1-100 µg/ml | Decreased survival ≥25 µg/ml; mitochondrial effects | [79] | |
| Cell Type | Parameters / Dose | Main Findings | Refs. | |
| HT22 hippocampal cells | 6 nm and 100 nm CeO, Al2O3 300 nm; 8, 16, 24 h; 0.04 M | Specific gene expression pattern for 6 nm CeO including induction of genes for neurological disease | [ | |
| PC12 cells | 5-80 nm; 24 or 72 h; 10, 20, 50, 100 µg/ml | Stimulation of NGF-induced differentiation; increased dopamine production; decreased ROS levels | [ | |
| Mn | Mesencephalic dopaminergic N27 cells | 20 nm or 100-900 nm aggregates; 3, 6, 9 h; 25-400 µg/ml | Internalization; cytotoxicity; autophagy; apoptosis. Cell death independent of oxidative stress | [ |
| Murine primary mesencephalic nerve cells | 20 nm or 100-900 nm aggregates; 3, 6, 9 h; 25-400 µg/ml | Increased cell death; decreased neurite length | [ | |
| Cu | Primary dorsal root ganglion cells | 40, 60, 80 nm; 24 h; 10-100 µM | Smaller particles and higher concentrations more toxic (morphological effects, increased LDH-release) | [ |
| Primary microglia | TiO2 20 nm, HAP 60 and 12 nm (short/long diameter), Fe3O4 45 nm; 2 h; 0.25 and 0.50 mg/ml | Cytokine production and NO production; strongest effects of TiO2 | [ | |
| Primary dorsal root ganglion cells | 25 nm diameter, 10-20µm length; 24 h; 0.1, 1, 5, 10 µg/ml | Decreased axonal regeneration in crush-lesioned ganglia from 1 µg/ml | [ | |
| Fullerene | Primary hippocampal neurons | 24, 48, 72 h; 1, 5, 25, 100 µM | Increased viability at 1 and 5 µM; increased DNA damage and apoptosis at 25 and 100 µM | [ |
| PC12 cells | 2.4-4.7 nm with/without thioglycolic coating; up to 17 days; 1 nM | Decreased cell viability and apoptosis induction, more prominent for smaller particles and without coating | [ | |
| Hippocampal slices | 5-20 nm primary particles, 115-704 nm aggregates; 10-7 – 10-4 g/ml; | Interference with both rectifying K+-channels and voltage-gated Na+-channels, affecting action potentials | [ | |
| Primary frontal cortex cells | CB 575 nm, Fe2O3 50 nm; TiO2 91 nm; 0.0001-300 µg/cm2 | Concentration-dependent effects (strongest by TiO2) on electrophysiological parameters. ROS increase by TiO2 | [ |